Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2023.102.14
- Author:
Chenyi REN
1
;
He CAO
2
;
Jing ZHENG
2
;
Wenjia SUN
2
;
Jianya ZHOU
2
Author Information
1. Department of Respiratory Disease, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China.
2. Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
- Publication Type:Journal Article
- Keywords:
Human epidermal growth factor receptor 2;
Lung neoplasms;
Targeted therapy
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Lung Neoplasms/genetics*;
Receptor, ErbB-2/genetics*;
Mutation;
Antineoplastic Agents/pharmacology*;
Signal Transduction;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2023;26(4):291-302
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common malignancy in the world and the leading cause of cancer death. Human epidermal growth factor receptor 2 (HER2) positive non-small cell lung cancer (NSCLC) refers to the NSCLC caused by mutation, amplification or overexpression of the HER2 gene, resulting in its dysfunction. HER2 is the most active receptor in the HER family and can combine with other members to form dimers, which can activate multiple signaling pathways and regulate cell proliferation, differentiation, migration and apoptosis. In NSCLC, HER2 positivity is usually considered a poor prognostic marker. At present, the diagnosis and treatment of HER2-positive NSCLC are not mature. Immunohistochemistry (IHC), next generation sequencing (NGS) and other technologies are often used to detect the positive status of HER2 mutation, amplification or overexpression. In previous studies, antitumor drugs did not show ideal therapeutic effects in HER2-positive NSCLC. However, in recent years, related researches have shown that antibody-drug conjugates (ADCs) and new tyrosine kinase inhibitors (TKIs) in targeted therapy show good antitumor activity against HER2 positive NSCLC. This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC, so as to provide reference for subsequent researches.
.
